“We know so much about Parkinson’s, but so little about people with Parkinson’s”
Author: Sophie BatesPublished: 30 April 2020
Prep: Cook: Serves:
‘Brain Fables’ aims to overhaul how we think about Parkinson’s – and suggests that it’s time to stop treating it as a single condition. We talk to the authors, Benjamin Stecher, who has young onset Parkinson’s, and Dr Alberto Espay, a professor of neurology, about the lessons learned from the research ‘failures’ that have been made so far, and why it’s crucial for scientists to find out more about individuals with Parkinson’s
Tells us about ‘Brain Fables’.
Dr Alberto Espay, professor of neurology: This book approaches neurodegenerative conditions in a way that has never been done before. We know so much about Parkinson’s, but so little about people with Parkinson’s. If we let the data speak, we would see that the current models we have created for Parkinson’s apply to virtually no one, and maybe that’s why every clinical trial aimed to slow the condition has failed. The main message is that unless we change the way we think and approach brain ageing conditions, we will continue to have failure after failure.
We view this book as an opportunity to have a frank discussion about what we know – but more importantly about what we think we know but don’t. We don’t want to remove hope, we want hope to be based on rational elements.
Benjamin Stecher, Parkinson’s advocate and consultant: ‘Brain Fables’ is like a ‘choose your own adventure’ because we’ve worked on our own elements and brought them together. My narrative brings the perspective of someone with Parkinson’s, and also the opinions of researchers that I’ve been in contact with, while Alberto brings in the science behind the arguments and his perspective as a researcher.
Each chapter is a journey of our individual research and experiences that led to our conclusions. Our stories complement one another because there are parts that build on each other and then there’s the overlapping narratives. Some may only want to read the research perspective, others the patient’s point of view and some might choose to read both.
How did the idea for ‘Brain Fables’ come about?
Benjamin: Alberto and I first began to communicate in January 2019, when I reached out to him for an interview on my website, Tomorrow Editionand found that his ideas about Parkinson’s resonated with me deeply. A lot of the conclusions he had reached were similar to my own, so we went from there.
Alberto: The original name for the book was going to be ‘Brain Fictions’, because of the idea that the narrative that has been created around Parkinson’s doesn’t hold true when you look at the data – so from a biological perspective it’s fictional.
Who is ‘Brain Fables’ aimed at?
Alberto: This book is aimed at anyone who is interested in brain ageing and what is being done to combat the symptoms of it as we delve into Parkinson’s and Alzheimer’s . We hope this will be of interest to foundations, the government and industries of health in the US – as they are the ones that invest in research into Parkinson’s.
What message do you hope readers will take away from ‘Brain Fables’?
Alberto: We are probably not going to be able to change the research process until there is enough outrage from the outside. People need to ask why they are investing in research that is not heading anywhere. This book hopes to, in many ways, shock people outside of neurology, as current research is either inconsistent, or if it is consistent it reflects on common ends of the process, not what is relevant to each individual. If we conduct a study with 100 people with Parkinson’s, we report on the averages as a way of understanding – but that means we know next to nothing about individuals with Parkinson’s.
This book is all about evidence and how this evidence conflicts with our concepts, definitions and boundaries for Parkinson’s. Unless we tackle this societally, we’re not going to get close to the precision of medicine that other fields have already accomplished.
We need to start considering the possibility that there will never be a cure for Parkinson’s but there will eventually be cures for well-defined sub types of Parkinson’s.
Benjamin: What we’re proposing is not a quick fix, it’s very much a long-term solution.
‘Brain Fables’ is set to be released inspring 2020. Find out more here.
Need to know
Benjamin Stecher is a Parkinson’s advocate and consultant for academia and industry based in Toronto, Canada. Since his Parkinson’s diagnosis at the age of 29, he has spent his time travelling the world to discover more about the condition and launched his website ‘Tomorrow Edition’.
Alberto Espay is a professor of neurology based in Ohio, United States. He is an advocate of precision medicine in neurodegenerative diseases.
To find out more about Parkinson’s research, please visit the EPDA website.
Visiting loved ones with Parkinson’s disease during the pandemic
What you need to consider this holiday season
4 days ago
Weight, sleep and depression linked to risk of cognitive problems in Parkinson’s
Researchers at the University of Pennsylvania, US, have found that people with early Parkinson’s disease are at higher risk of developing cognitive impairments if they are overweight, have disruptive sleep behaviours or experience symptoms of depression. Evaluating data from 405 people, the researchers used statistical analysis to identify relationships between certain characteristics and changes in patient cognition over time. Their findings suggest that factors such as high body mass index (BMI) or excessive sleepiness are associated with a faster rate of cognitive decline in Parkinson’s disease. The researchers wrote: “Despite its common and devastating occurrence, treatment of [cognitive impairments] in [Parkinson’s disease] is limited and no medications slow its onset or progression. However, identification of treatable or modifiable comorbidities that affect the rate of progression of [cognitive impairments] in [Parkinson’s disease] could provide opportunities for early intervention and improved prognosis.”
Gene screening technique could offer insights on Parkinson’s disease
Researchers from the Massachusetts Institute of Technology (MIT), US, will investigate genes that could protect cells in the brain against Parkinson’s disease. An award from US non-profit G Harold and Leila Y Mathers Foundation will allow scientists to use a mouse model screening technique to find out more about the condition. Individually deleting each of the 22,000 genes present in mice neurons will help identify which genes are linked to neuron survival – and offer insights that could lead to new treatments for the condition. Dr Myriam Heiman, an Associate Professor at MIT, said: “There is currently no molecular explanation for the brain cell loss seen in Parkinson’s disease or a cure for this devastating disease. I’m extremely grateful for this generous support and recognition of our work from the Mathers Foundation, and hope that our study will elucidate new therapeutic targets for the treatment and even prevention of Parkinson’s…
Can equine-assisted therapy benefit people with Parkinson’s disease?
Researchers from Texas Woman’s University, US, are investigating how equine-assisted therapy – which involves working with horses to promote wellbeing – can benefit people with Parkinson’s disease. As part of the five-month study, funded by the non-profit Human Animal Bond Research Institute, 30 men with Parkinson’s disease will be randomly assigned to participate in equine-assisted therapy or simulated horseback riding. The participants’ motor performance, balance, gait and symptoms related to Parkinson’s disease will be assessed before, during and after the therapy. Rhett Rigby, principal investigator of the study, said: “There is currently no known study that utilises equine-assisted therapy as an intervention treatment for those with Parkinson’s disease. Our research could have a significant impact on an understudied population and help contribute to the existing literature on human-animal interaction.”